Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997457 | 0.91 | CTSB (0.31) | — | |
| SCHEMBL3313061 | 0.80 | CTSB (0.35) | ALDH1A1 | |
| SCHEMBL3306838 | 0.78 | CTSB (0.34) | — | |
| SCHEMBL3307886 | 0.77 | CTSB (0.42) | ALDH1A1 | |
| SCHEMBL13502613 | 0.76 | CTSB (0.41) | — | |
| SCHEMBL996662 | 0.76 | CTSB (0.41) | — | |
| SCHEMBL996664 | 0.76 | CTSB (0.41) | — | |
| SCHEMBL3309557 | 0.75 | CTSB (0.43) | ALDH1A1 | |
| SCHEMBL3309377 | 0.75 | CTSB (0.41) | ALDH1A1 | |
| SCHEMBL997460 | 0.74 | CTSB (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919898-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-01-26 | — | — | EP | disclosed |
| US-7666834-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-02-23 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HCCS, CBR1, CYP2B6 | ALDH1A1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.